iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity
iBio has initiated dosing in its Phase 1 clinical trial for IBIO-600, a long-acting monoclonal antibody aimed at preserving muscle and improving body composition in adults with obesity. This milestone marks the company's transition to a clinical-stage biotech firm, showcasing progress in its AI-driven discovery platform and potential combination wi…